A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma

NCT03421730 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Wheezing
Reactive Airway Disease
Mild Asthma

Interventions

COMBINATION_PRODUCT: VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System
COMBINATION_PRODUCT: 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer

Sponsor

Vectura Limited